Physicochemical Properties
| Molecular Formula | C21H19N3O5 |
| Molecular Weight | 393.39 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 1.02 Μm (hAChE)[1]. IC50: 7.03 μM (hBChE)[1]. |
| ln Vitro | NLRP3-IN-33 (12o) (1-30 μM; 24 h) had no significant cytotoxic effect in PC-12 cells[1]. NLRP3-IN-33 has antioxidant activity and can inhibit the production of free radicals with an IC50 value of 6.19 μM. 12o (1-20 μM; 24 h) effectively alleviated oxidative stress induced by H2O2 (600 μM; 24 h) in PC-1 cells and had a neuroprotective effect[1]. NLRP3-IN-33 (1-20 μM; 24 h) also inhibited the activation of NLRP3 inflammasome in PC-1 cells and reduced mitochondrial-induced reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) damage caused by LPS (1 μg/mL) and ATP (5 mM) in HMC-3 cells[1]. |
| ln Vivo | NLRP3-IN-33 (12o) (0.05-0.02 mg/mL) can more effectively reduce mitochondrial and cellular oxidative stress in the Drosophila AD model at a low dose (0.05 mg/mL) [1]. LRP3-IN-33 (5 mg/kg; intraperitoneal injection; once a day for 22 consecutive days) can improve memory impairment and cognitive impairment in the Scopolamine (HY-N0296) (1.4 mg/kg; intraperitoneal injection; once a day for 5 consecutive days)-induced AD mouse model [1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: HMC-3 Concentration: 12.5 μM, 25 μM Incubation Duration: 24 h Experimental Results: Inhibited the NLRP3 inflammasome activation and caspase-1 release. Significantly decreased the expression of NF-κB and NLRP3 proteins. |
| Animal Protocol |
Animal/Disease Models:Alzheimer's disease (AD) fractional model[1] Doses: 1 mg/kg, 5 mg/kg Route of Administration: Intraperitoneal injection (i.p.); Once daily for 22 days. Received scopolamine (HY-N0296) (1.4 mg/kg; i.p.; once daily for 5 days) on the last 5 days of the experiment (day 18 to day 22). Experimental Results: Significantly shortened escape latency time as compared to the scopolamine-treated group. |
| References |
[1]. Design, Synthesis, and Biological Evaluation of Ferulic Acid Template-Based Novel Multifunctional Ligands Targeting NLRP3 Inflammasome for the Management of Alzheimer's Disease. ACS Chem Neurosci. 2024;15(7):1388-1414. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5420 mL | 12.7100 mL | 25.4201 mL | |
| 5 mM | 0.5084 mL | 2.5420 mL | 5.0840 mL | |
| 10 mM | 0.2542 mL | 1.2710 mL | 2.5420 mL |